Save Money While Seeking the Sun: Cost Effective Winter Stays in Egypt
25.1.2023 11:00:00 EET | Business Wire | Press release
Spending the winter season in a warm place has always been popular, whether you’re a digital nomad or a pensioner. But, the rising cost of living over the past year could cause many to reconsider whether, or how, they travel.
While Egypt has long been on travelers’ radar, thanks to its low-cost of living, it has now become a popular long-stay winter destination. In fact, a one month stay in a luxurious three or four-star-hotel can cost less than living in the Western European countries for the same amount of time.
Research collated by the Egyptian Government from a variety of tour operators shows a four-week winter sun stay costs, on average, €1 218 per couple. This includes 160€ per person for a return flight, 25€ per couple for a double room in a four-star hotel and 8€ per person for a three-course dinner at a local restaurant.
In comparison, the average monthly cost of a two-person household for gas, energy, food and beverages is 1 396€ in Italy, 1 509€ in France and 1 601€ in Germany during the winter.
The Egyptian Government is currently promoting and facilitating month long stays at a wide variety of hotels.
Amr El-Kady, CEO of Egyptian Tourism Authority, said: “Egypt is always happy to welcome travelers from Europe. We are doing our best to make the stay as effortless and affordable as possible. This winter season, we invite you to spend the cold months under the kind Egyptian sun, saving the budget and filling life with fantastic new experiences”.
What does Egypt have to offer? Plenty.
From Cairo to Luxor, from the beguiling desert to the lush delta of the Nile, Egypt is a traveler's dream. Whether diving into the rich underwater world of the Red Sea, sailing on the Nile towards the sunset or tracing the secrets of the ancient Egyptians in stunning temple complexes, the land of the pharaohs has something to offer to every visitor.
Among the most famous destinations is the capital Cairo, where you can immerse yourself in all eras of Egyptian history in the Egyptian Museum, and visit the famous Pyramids of Giza with the impressive Sphinx. Another highlight is the city of Luxor, which offers some spectacular wonders, that include the Valley of the Kings, the Temple of Karnak and the legendary Luxor Temple, which is one of the absolute must-sees on any trip and continues to enchant with ancient stories.
If you prefer active and adventurous activities, you don't have to look far. Egypt is not only a diver's paradise, but also offers desert excursions, Nile cruises and breathtaking landscapes such as the Colored Canyon National Park on the Sinai Peninsula. While ecotourism is becoming increasingly popular in the country and even spiritual tours are offered, Egypt is also known for particularly high-quality spa treatments.
A variety of flight connections ensure a pleasant way to get there. There are direct flights to resorts of Egypt from almost every major European city.
Find out what else Egypt has to offer on Egypt travel - Home (experienceegypt.eg)
- ENDS –
Destination images can be downloaded here
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005579/en/
Contact information
External Press office
Philipp Koneev, Senior Account Manager, MC Group
p.koneev@mcgroup.com
+49 30 65000‑540
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
